Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Zimmer biomet holdings inc | Rare Historical Photos

3 Healthtech Stocks Making Healthcare More Accessible

The healthcare market is fueling digital transformation by improving efficiency and fostering personalized care, making it an attractive investment opportunity. Hence, investors might consider investing in healthcare stocks, such as Teladoc Health (TDOC), Zimmer Biomet Holdings (ZBH), and Cardinal Health (CAH). Read more….

StockNews.com

3 Healthcare Innovators Advancing Medical Technology

The healthcare industry is set for growth due to evolving healthcare demands and the rapid evolution of medical technologies. Hence, investors might consider investing in healthcare stocks, Becton, Dickinson and Co. (BDX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC). Read more….

StockNews.com

3 Healthcare Technology Companies Revolutionizing Patient Care

The healthcare technology market is well-poised for long-term growth, thanks to the growing demand for medical devices, cutting-edge technologies, and changing patient care systems. Thus, it could be wise to buy fundamentally solid healthcare technology stocks Zimmer Biomet Holdings (ZBH), STERIS (STE), and Tactile Systems Technology (TCMD), which are revolutionizing…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Undervalued Health-Tech Stocks to Buy for Long-Term Growth

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical areas, as well as the demand for personalized medicine. Thus, it could be wise to invest in fundamentally solid health-tech stocks McKesson (MCK), Cardinal Health (CAH), and Zimmer Biomet (ZBH) poised for long-term…

StockNews.com

3 Medical Devices Stocks Poised for Solid Growth

The medical device sector is evolving, driven by rising demand for precision technology in diagnostics. Therefore, it could be ideal to buy fundamentally solid medical device stocks Stryker Corp (SYK), Axogen (AXGN), and Zimmer Biomet Holdings (ZBH), which look poised for substantial growth. Read more….

StockNews.com

3 Oversold Stocks With Buy Signals

Investing in oversold stocks can be a potentially profitable strategy for investors who are willing to take calculated risks and have a long-term perspective. Amid this backdrop, investors could consider buying fundamentally strong oversold stocks Comcast (CMCSA), Northrop Grumman (NOC), and Zimmer Biomet Holdings (ZBH) with an RSI below 30.…

StockNews.com

Should you Buy or Sell These 3 Medical Stocks?

Thanks to the rising awareness of the benefits of digital health services and technological advancements, the medical industry is poised for remarkable growth. While the industry outlook may seem promising, should one buy or sell Medtronic (MDT), Zimmer Biomet (ZBH), and Merit Medical (MMSI)? Read more to find out.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Wide-Moat Stocks to Buy in June

The stock market has been witnessing wild swings lately amid growing concerns over the Fed’s aggressive interest rate hikes to combat the multi-decade high inflation, supply bottlenecks, ongoing geopolitical crisis, and possibility of a recession. However, wide-moat stocks have competitive advantages and tend to outperform their peers in the long…

StockNews.com

Are Medical Device Stocks Good Investments During a Recession?

The stock market has witnessed a massive sell-off lately on concerns over the Fed’s aggressive interest rate hikes to fight the decade-high inflation. Many analysts expect the economy to slip into recession due to the Fed’s monetary policy tightening. Since the medical device industry is known to be one of…

StockNews.com

Zimmer Biomet Raises, Tightens FY22 Outlook after Q1 Earnings Surpass Estimates

Zimmer Biomet Holdings Inc's (NYSE:ZBH) Q1 sales increased by 3.9% Y/Y to $1.66 billion (up 6.8% on a constant currency basis), beating the consensus of $1.59 billion. Adjusted EPS was $1.61, which came in above the consensus of $1.41 and $1.55 a year ago. "We are encouraged by the better than expected results…

Benzinga

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.